The differential expression of tubulin isotypes in cancers, such as overexpression of βI and βIII‐tubulin in breast and lung cancers, and highly expressed βVI‐tubulin in normal blood cells has triggered great interest in designing specific tubulin isotype‐binding anticancer therapies.48 This evidence concerns the gene CACNA1A and lung cancer.